| Field | Row 1 |
|---|---|
| adsh | 0000012208-25-000026 |
| cik | 12208 |
| name | BIO-RAD LABORATORIES, INC. |
| sic | 3826 |
| countryba | US |
| stprba | CA |
| cityba | HERCULES |
| zipba | 94547 |
| bas1 | 1000 ALFRED NOBEL DRIVE |
| bas2 | |
| baph | 5107247000 |
| countryma | US |
| stprma | CA |
| cityma | HERCULES |
| zipma | 94547 |
| mas1 | 1000 ALFRED NOBEL DRIVE |
| mas2 | |
| countryinc | US |
| stprinc | DE |
| ein | 941381833 |
| former | BIO RAD LABORATORIES INC |
| changed | 19920703 |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250501 |
| accepted | 2025-05-01 16:31:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | bio-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0000012208-25-000026 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 433800000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Common Stock Shares Issued | 25191463.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Common Class A; | ||
| 0000012208-25-000026 | 20240331 | Cost Of Goods And Services Sold | 600000.0000 | USD | 1 | us-gaap/2025 | Business Segments= All Other Segments; | ||
| 0000012208-25-000026 | 20250331 | Cost Of Goods And Services Sold | 279400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Deferred Income Tax Liabilities Net | 840800000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Earnings Per Share Diluted | 2.2900 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -1800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Employee Related Liabilities Current | 157400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Gross Profit | 306000000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Operating Segments; | ||
| 0000012208-25-000026 | 20240331 | Interest Expense | 12300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Interest Expense | 12000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Inventory Net | 790100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Long Term Investments | 4839200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Marketable Securities Unrealized Gain Loss | 31800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Net Income Loss | 64000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Operating Income Loss | 44600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Operating Lease Liability Noncurrent | 126300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Other Assets Current | 30700000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Loss Net Of Tax | -89900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 123600000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Translation Adjustment; | ||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 128400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Proceeds From Issuance Of Common Stock | 4300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Retained Earnings Accumulated Deficit | 7416400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 241700000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Life Science; | ||
| 0000012208-25-000026 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 252900000.0000 | USD | 1 | us-gaap/2025 | Geographical= U S; | ||
| 0000012208-25-000026 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 199800000.0000 | USD | 1 | us-gaap/2025 | Geographical= Europe; | ||
| 0000012208-25-000026 | 20231231 | Stockholders Equity | -2800000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0000012208-25-000026 | 20231231 | Stockholders Equity | 449100000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20231231 | Stockholders Equity | 9260600000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20240331 | Stockholders Equity | 9051300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Stockholders Equity | -1800000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0000012208-25-000026 | 20250331 | Stockholders Equity | 7480400000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20240331 | Stock Issued During Period Value Treasury Stock Reissued | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20240331 | Stock Issued During Period Value Treasury Stock Reissued | 1700000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20250331 | Stock Issued During Period Value Treasury Stock Reissued | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20241231 | Treasury Stock Common Shares | 2254728.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20240331 | Treasury Stock Value Acquired Cost Method | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20250331 | Treasury Stock Value Acquired Cost Method | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20250331 | Accounts Receivable Net Current | 424700000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Additional Paid In Capital | 463200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20250331 | Allowance For Doubtful Accounts Receivable Current | 7800000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Assets | 491700000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Clinical Diagnostics; Consolidation Items= Operating Segments; | ||
| 0000012208-25-000026 | 20241231 | Assets | 9364100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Assets | 308100000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Life Science; Consolidation Items= Operating Segments; | ||
| 0000012208-25-000026 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 489800000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Cost Of Goods And Services Sold | 0.0000 | USD | 1 | us-gaap/2025 | Business Segments= All Other Segments; | ||
| 0000012208-25-000026 | 20240331 | Foreign Currency Transaction Gain Loss Before Tax | 2000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Foreign Currency Transaction Gain Loss Before Tax | 2000000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Material Reconciling Items; | ||
| 0000012208-25-000026 | 20250331 | Goodwill | 291500000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Life Science; | ||
| 0000012208-25-000026 | 20250331 | Gross Profit | 0.0000 | USD | 1 | us-gaap/2025 | Business Segments= All Other Segments; | ||
| 0000012208-25-000026 | 20250331 | Gross Profit | 128400000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Life Science; | ||
| 0000012208-25-000026 | 20250331 | Liabilities | 2847500000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Net Income Loss | 383900000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20250331 | Operating Income Loss | 23700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent | -1400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -89900000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20250331 | Other Liabilities Current | 131700000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Paymentsforproceedsfromderivativeinstrumentsoperatingactivities | 8300000.0000 | USD | 1 | 0000012208-25-000026 | |||
| 0000012208-25-000026 | 20241231 | Preferred Stock Shares Authorized | 7500000.0000 | shares | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Preferred Units Outstanding | 0.0000 | shares | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Prepaid Expense Current | 122600000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Proceeds From Issuance Of Common Stock | 5500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Research And Development Expense | 66400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Stockholders Equity | -425800000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Translation Adjustment; | ||
| 0000012208-25-000026 | 20240331 | Stockholders Equity | 462700000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20241231 | Stockholders Equity | -538200000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20241231 | Stockholders Equity | 7416400000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20250331 | Stockholders Equity | -409800000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20250331 | Stockholders Equity | -416800000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Translation Adjustment; | ||
| 0000012208-25-000026 | 20250331 | Stock Issued During Period Value Treasury Stock Reissued | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20250331 | Stock Repurchased During Period Excise Tax Amount | 0.0000 | USD | 1 | 0000012208-25-000026 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20240331 | Treasury Stock Reissued At Lower Than Repurchase Price | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20240331 | Treasury Stock Value Acquired Cost Method | 4700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Treasury Stock Value Acquired Cost Method | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20250331 | Treasury Stock Value Acquired Cost Method | 100900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Treasury Stock Value Acquired Cost Method | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20250331 | Payments Of Debt Issuance Costs | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Accounts Receivable Net Current | 452500000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20241231 | Allowance For Doubtful Accounts Receivable Current | 9200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Assets | 9526900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Assets Current | 3030300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 33300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Common Stock Shares Outstanding | 22936735.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Common Class A; | ||
| 0000012208-25-000026 | 20250331 | Common Stock Shares Outstanding | 5070337.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Common Class B; | ||
| 0000012208-25-000026 | 20241231 | Common Stock Value | 0.0000 | USD | 0 | us-gaap/2025 | Class Of Stock= Common Class A; | ||
| 0000012208-25-000026 | 20240331 | Cost Of Goods And Services Sold | 174300000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Clinical Diagnostics; | ||
| 0000012208-25-000026 | 20241231 | Deferred Income Tax Liabilities Net | 818000000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Earnings Per Share Basic | 2.2900 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Employee Related Liabilities Current | 124200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Foreign Currency Transaction Gain Loss Before Tax | 2700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Foreign Currency Transaction Gain Loss Before Tax | 2700000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Material Reconciling Items; | ||
| 0000012208-25-000026 | 20250331 | Goodwill | 123100000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Clinical Diagnostics; | ||
| 0000012208-25-000026 | 20240331 | Gross Profit | -100000.0000 | USD | 1 | us-gaap/2025 | Business Segments= All Other Segments; | ||
| 0000012208-25-000026 | 20240331 | Gross Profit | 131700000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Life Science; | ||
| 0000012208-25-000026 | 20250331 | Gross Profit | 306000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Net Cash Provided By Used In Financing Activities | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Net Cash Provided By Used In Investing Activities | -43100000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Net Cash Provided By Used In Operating Activities | 129900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20250331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20241231 | Operating Lease Liability Current | 41700000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 128400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 128400000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20250331 | Other Nonoperating Income Expense | 37200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Other Nonoperating Income Expense | -200000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Defined Benefit Plans Adjustment; Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20240331 | Paymentsforproceedsfromderivativeinstrumentsoperatingactivities | -2200000.0000 | USD | 1 | 0000012208-25-000026 | |||
| 0000012208-25-000026 | 20250331 | Payments For Repurchase Of Common Stock | 101900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Payments To Suppliers And Employees | 560300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Proceeds From Other Operating Activities | 15800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Proceeds From Sale Of Available For Sale Securities Debt | 331500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 528100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 528500000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Repayments Of Long Term Debt | 200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 117200000.0000 | USD | 1 | us-gaap/2025 | Geographical= Asia Pacific; | ||
| 0000012208-25-000026 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 228600000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Life Science; | ||
| 0000012208-25-000026 | 20250331 | Short Term Investments | 1139000000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20231231 | Stockholders Equity | 8741200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20231231 | Stockholders Equity | -334100000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Translation Adjustment; | ||
| 0000012208-25-000026 | 20240331 | Stockholders Equity | -425900000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20240331 | Stockholders Equity | 0.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20240331 | Stockholders Equity | 9644500000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20241231 | Taxes Payable Current | 31200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Treasury Stock Value Acquired Cost Method | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20240331 | Treasury Stock Value Acquired Cost Method | 4700000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -538200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20250331 | Assets | 482000000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Clinical Diagnostics; Consolidation Items= Operating Segments; | ||
| 0000012208-25-000026 | 20240331 | Cash And Cash Equivalents At Carrying Value | 433300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Cash And Cash Equivalents At Carrying Value | 488100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 29400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Common Stock Shares Outstanding | 5074409.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Common Class B; | ||
| 0000012208-25-000026 | 20250331 | Common Stock Shares Outstanding | 22562875.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Common Class A; | ||
| 0000012208-25-000026 | 20241231 | Common Stock Value | 0.0000 | USD | 0 | us-gaap/2025 | Class Of Stock= Common Class B; | ||
| 0000012208-25-000026 | 20240331 | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | 294000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Earnings Per Share Diluted | 13.4500 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Goodwill | 291500000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Life Science; | ||
| 0000012208-25-000026 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 491100000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Interest Expense | 12000000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Material Reconciling Items; Income Statement Location= Interest Expense; | ||
| 0000012208-25-000026 | 20241231 | Liabilities | 2794800000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Marketable Securities Unrealized Gain Loss | 422200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Marketable Securities Unrealized Gain Loss | 31800000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Material Reconciling Items; | ||
| 0000012208-25-000026 | 20240331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20240331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20250331 | Net Income Loss | 64000000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Loss Net Of Tax | 400000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 5000000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -89900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | 400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | 5000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Other Nonoperating Income Expense | 200000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20240331 | Payments For Repurchase Of Common Stock | 4700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Research And Development Expense | 66400000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Operating Segments; | ||
| 0000012208-25-000026 | 20240331 | Restricted Cash Current | 100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20240331 | Assets | 291700000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Life Science; Consolidation Items= Operating Segments; | ||
| 0000012208-25-000026 | 20250331 | Common Stock Shares Issued | 25195533.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Common Class A; | ||
| 0000012208-25-000026 | 20250331 | Common Stock Value | 0.0000 | USD | 0 | us-gaap/2025 | Class Of Stock= Common Class A; | ||
| 0000012208-25-000026 | 20240331 | Gross Profit | 325900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Gross Profit | 325900000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Operating Segments; | ||
| 0000012208-25-000026 | 20240331 | Income Tax Expense Benefit | 107200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Liabilities And Stockholders Equity | 9526900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Net Income Loss | 383900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20250331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20250331 | Operating Lease Liability Current | 41300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Operating Lease Right Of Use Asset | 160500000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Operating Lease Right Of Use Asset | 153200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Other Assets Current | 36000000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Loss Net Of Tax | -89900000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20241231 | Other Liabilities Current | 147200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Other Liabilities Noncurrent | 173100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Other Nonoperating Income Expense | 34600000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Material Reconciling Items; | ||
| 0000012208-25-000026 | 20240331 | Payments To Acquire Investments | 406500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Proceeds From Customers | 638300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Research And Development Expense | 73500000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Operating Segments; | ||
| 0000012208-25-000026 | 20231231 | Stockholders Equity | -632500000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20240331 | Stockholders Equity | -630000000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20241231 | Stockholders Equity | 6569300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Stockholders Equity | 4000000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0000012208-25-000026 | 20241231 | Stockholders Equity | 0.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20250331 | Stockholders Equity | 475700000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20250331 | Treasury Stock Value Acquired Cost Method | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20250331 | Treasury Stock Value Acquired Cost Method | 100900000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 27941000.0000 | shares | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Selling General And Administrative Expense | 208800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Short Term Investments | 1176400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20231231 | Stockholders Equity | 900000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0000012208-25-000026 | 20231231 | Stockholders Equity | 0.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20240331 | Stockholders Equity | 1300000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0000012208-25-000026 | 20241231 | Stockholders Equity | 463200000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20250331 | Stockholders Equity | 9000000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0000012208-25-000026 | 20250331 | Stockholders Equity | 0.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20250331 | Stock Repurchased During Period Excise Tax Amount | 1000000.0000 | USD | 1 | 0000012208-25-000026 | |||
| 0000012208-25-000026 | 20250331 | Stock Repurchased During Period Excise Tax Amount | 0.0000 | USD | 1 | 0000012208-25-000026 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20250331 | Taxes Payable Current | 37100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Treasury Stock Value | 772100000.0000 | USD | 0 | us-gaap/2025 | Class Of Stock= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20250331 | Treasury Stock Value Acquired Cost Method | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20250331 | Accounts Payable Current | 137900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -409800000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 15300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Assets | 0.0000 | USD | 0 | us-gaap/2025 | Business Segments= All Other Segments; Consolidation Items= Operating Segments; | ||
| 0000012208-25-000026 | 20250331 | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | 192400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Cost Of Goods And Services Sold | 179200000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Clinical Diagnostics; | ||
| 0000012208-25-000026 | 20241231 | Goodwill | 410500000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Goodwill | 414600000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Gross Profit | 194300000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Clinical Diagnostics; | ||
| 0000012208-25-000026 | 20240331 | Interest Expense | 12300000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Material Reconciling Items; Income Statement Location= Interest Expense; | ||
| 0000012208-25-000026 | 20240331 | Interest Paid Net | 22400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Inventory Net | 760000000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Liabilities And Stockholders Equity | 9364100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Liabilities Current | 467800000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Long Term Debt Noncurrent | 1200400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Net Cash Provided By Used In Financing Activities | -97700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Net Cash Provided By Used In Investing Activities | 2900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Net Cash Provided By Used In Operating Activities | 69800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Notes And Loans Payable Current | 1200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Other Assets | 101900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 123600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 128400000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20240331 | Other Nonoperating Income Expense | 34600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Other Nonoperating Income Expense | 100000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Defined Benefit Plans Adjustment; Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20250331 | Payments To Acquire Property Plant And Equipment | 34400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Proceeds From Customers | 640000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Proceeds From Other Operating Activities | 16300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Research And Development Expense | 73500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Restricted Cash Current | 1300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 200200000.0000 | USD | 1 | us-gaap/2025 | Geographical= Europe; | ||
| 0000012208-25-000026 | 20241231 | Accounts Payable Current | 122300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Additional Paid In Capital | 475700000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Assets | 0.0000 | USD | 0 | us-gaap/2025 | Business Segments= All Other Segments; Consolidation Items= Operating Segments; | ||
| 0000012208-25-000026 | 20250331 | Common Stock Shares Issued | 5070337.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Common Class B; | ||
| 0000012208-25-000026 | 20250331 | Cost Of Goods And Services Sold | 100200000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Life Science; | ||
| 0000012208-25-000026 | 20241231 | Goodwill | 119000000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Clinical Diagnostics; | ||
| 0000012208-25-000026 | 20240331 | Income Taxes Paid Net | 3800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Income Taxes Paid Net | 7900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Income Tax Expense Benefit | 19400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Intangible Assets Net Excluding Goodwill | 296100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Interest Paid Net | 22200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Liabilities Current | 506600000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Long Term Debt Noncurrent | 1200700000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Marketable Securities Unrealized Gain Loss | 422200000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Material Reconciling Items; | ||
| 0000012208-25-000026 | 20250331 | Notes And Loans Payable Current | 1200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent | 200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -91700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Loss Net Of Tax | 1400000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0000012208-25-000026 | 20240331 | Other Comprehensive Income Loss Net Of Tax | -91700000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Translation Adjustment; | ||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20250331 | Other Nonoperating Income Expense | 37200000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Material Reconciling Items; | ||
| 0000012208-25-000026 | 20250331 | Other Nonoperating Income Expense | 500000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 15300000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 15300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 15300000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0000012208-25-000026 | 20250331 | Assets Current | 3036600000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Cash And Cash Equivalents At Carrying Value | 521400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 404400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 523100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Common Stock Shares Issued | 5074409.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Common Class B; | ||
| 0000012208-25-000026 | 20250331 | Common Stock Value | 0.0000 | USD | 0 | us-gaap/2025 | Class Of Stock= Common Class B; | ||
| 0000012208-25-000026 | 20240331 | Cost Of Goods And Services Sold | 284900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Payments Of Debt Issuance Costs | 600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 72100000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Proceeds From Sale Of Available For Sale Securities Debt | 171200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Repayments Of Long Term Debt | 100000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Retained Earnings Accumulated Deficit | 7480400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 585400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2025 | Business Segments= All Other Segments; | ||
| 0000012208-25-000026 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 39800000.0000 | USD | 1 | us-gaap/2025 | Geographical= Americas; | ||
| 0000012208-25-000026 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 104100000.0000 | USD | 1 | us-gaap/2025 | Geographical= Asia Pacific; | ||
| 0000012208-25-000026 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 241700000.0000 | USD | 1 | us-gaap/2025 | Geographical= U S; | ||
| 0000012208-25-000026 | 20240331 | Selling General And Administrative Expense | 214900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20231231 | Stockholders Equity | -336000000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20240331 | Stockholders Equity | -1400000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0000012208-25-000026 | 20241231 | Stockholders Equity | -540400000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Translation Adjustment; | ||
| 0000012208-25-000026 | 20250331 | Stockholders Equity | -2000000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0000012208-25-000026 | 20250331 | Stockholders Equity | -866900000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20240331 | Stock Issued During Period Value Treasury Stock Reissued | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20250331 | Stock Issued During Period Value Treasury Stock Reissued | 2800000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20250331 | Stock Repurchased During Period Excise Tax Amount | 1000000.0000 | USD | 1 | 0000012208-25-000026 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20240331 | Treasury Stock Reissued At Lower Than Repurchase Price | 5500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Selling General And Administrative Expense | 214900000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Operating Segments; | ||
| 0000012208-25-000026 | 20241231 | Stockholders Equity | -772100000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20250331 | Stockholders Equity | 6679400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Stock Issued During Period Value Treasury Stock Reissued | 4300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Stock Issued During Period Value Treasury Stock Reissued | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0000012208-25-000026 | 20250331 | Stock Repurchased During Period Excise Tax Amount | 0.0000 | USD | 1 | 0000012208-25-000026 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000012208-25-000026 | 20250331 | Stock Repurchased During Period Excise Tax Amount | 0.0000 | USD | 1 | 0000012208-25-000026 | Equity Components= Additional Paid In Capital; | ||
| 0000012208-25-000026 | 20250331 | Treasury Stock Common Shares | 2632658.0000 | shares | 0 | us-gaap/2025 | Class Of Stock= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 28537000.0000 | shares | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 27955000.0000 | shares | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 28518000.0000 | shares | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Cost Of Goods And Services Sold | 110000000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Life Science; | ||
| 0000012208-25-000026 | 20240331 | Earnings Per Share Basic | 13.4600 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Gross Profit | 177600000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Clinical Diagnostics; | ||
| 0000012208-25-000026 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 83400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20241231 | Intangible Assets Net Excluding Goodwill | 293600000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Long Term Investments | 4994200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20250331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20241231 | Operating Lease Liability Noncurrent | 131400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Other Assets | 103700000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Other Comprehensive Income Loss Net Of Tax | -200000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0000012208-25-000026 | 20241231 | Other Liabilities Noncurrent | 177200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Payments To Acquire Investments | 153400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Payments To Acquire Property Plant And Equipment | 40200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Payments To Suppliers And Employees | 488000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Prepaid Expense Current | 125400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 19500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Restricted Cash Noncurrent | 400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20250331 | Restricted Cash Noncurrent | 400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 610800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0000012208-25-000026 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 500000.0000 | USD | 1 | us-gaap/2025 | Business Segments= All Other Segments; | ||
| 0000012208-25-000026 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 368600000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Clinical Diagnostics; | ||
| 0000012208-25-000026 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 40500000.0000 | USD | 1 | us-gaap/2025 | Geographical= Americas; | ||
| 0000012208-25-000026 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 356800000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Clinical Diagnostics; | ||
| 0000012208-25-000026 | 20250331 | Selling General And Administrative Expense | 208800000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Operating Segments; | ||
| 0000012208-25-000026 | 20250331 | Stock Issued During Period Value Treasury Stock Reissued | 7100000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20240331 | Treasury Stock Reissued At Lower Than Repurchase Price | 7200000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20250331 | Treasury Stock Value | 866900000.0000 | USD | 0 | us-gaap/2025 | Class Of Stock= Treasury Stock Common; | ||
| 0000012208-25-000026 | 20240331 | Treasury Stock Value Acquired Cost Method | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents At Carrying Value | us-gaap/2025 | 0 | 0 | monetary | I | D | Cash and Cash Equivalent | Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2025 | 0 | 0 | monetary | D | D | Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation | Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2025 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | Amount after tax of other comprehensive income (loss) attributable to parent entity. |
| Operating Lease Liability Noncurrent | us-gaap/2025 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2025 | 0 | 0 | monetary | D | D | Cash Provided by (Used in) Investing Activity, Including Discontinued Operation | Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets. |
| Earnings Per Share Diluted | us-gaap/2025 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2025 | 0 | 0 | monetary | D | D | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent | Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent. |
| Employee Related Liabilities Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Employee-related Liabilities, Current | Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Other Liabilities Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Other Liabilities, Current | Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. |
| Foreign Currency Transaction Gain Loss Before Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | Gain (Loss), Foreign Currency Transaction, before Tax | Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2025 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Proceeds From Issuance Of Common Stock | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Common Stock | The cash inflow from the additional capital contribution to the entity. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2025 | 0 | 0 | monetary | D | D | Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation | Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Stock Repurchased During Period Excise Tax Amount | 0000012208-25-000026 | 1 | 0 | monetary | D | D | Stock Repurchased During Period, Excise Tax, Amount | Stock Repurchased During Period, Excise Tax, Amount |
| Selling General And Administrative Expense | us-gaap/2025 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Short Term Investments | us-gaap/2025 | 0 | 0 | monetary | I | D | Short-Term Investments | Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. |
| Additional Paid In Capital | us-gaap/2025 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Common Stock Shares Issued | us-gaap/2025 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Proceeds From Customers | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from Customers | Cash receipts from customers during the current period which are usually for sales of goods and services. |
| Paymentsforproceedsfromderivativeinstrumentsoperatingactivities | 0000012208-25-000026 | 1 | 0 | monetary | D | C | Payments for (proceeds from) derivative instruments, operating activities | Payments for (proceeds from) derivative instruments, operating activities |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2025 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Deferred Income Tax Liabilities Net | us-gaap/2025 | 0 | 0 | monetary | I | C | Deferred Income Tax Liabilities, Net | Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2025 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Long Term Debt Noncurrent | us-gaap/2025 | 0 | 0 | monetary | I | C | Long-Term Debt, Excluding Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. |
| Payments For Repurchase Of Common Stock | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments for Repurchase of Common Stock | The cash outflow to reacquire common stock during the period. |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale | Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). |
| Operating Income Loss | us-gaap/2025 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Research And Development Expense | us-gaap/2025 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2025 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Accounts Receivable Net Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Notes And Loans Payable Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Notes and Loans Payable, Current | Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer. |
| Operating Lease Liability Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Operating Lease Right Of Use Asset | us-gaap/2025 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Assets | us-gaap/2025 | 0 | 0 | monetary | I | D | Other Assets | Amount of assets classified as other. |
| Other Liabilities Noncurrent | us-gaap/2025 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2025 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Restricted Cash Noncurrent | us-gaap/2025 | 0 | 0 | monetary | I | D | Restricted Cash, Noncurrent | Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. |
| Stock Issued During Period Value Treasury Stock Reissued | us-gaap/2025 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Treasury Stock Reissued | Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement. |
| Assets Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Earnings Per Share Basic | us-gaap/2025 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Payments To Acquire Property Plant And Equipment | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Interest Expense | us-gaap/2025 | 0 | 0 | monetary | D | D | Interest Expense, Operating and Nonoperating | Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. |
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | us-gaap/2025 | 0 | 0 | monetary | I | D | Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization | Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. |
| Liabilities Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2025 | 0 | 0 | monetary | D | D | Cash Provided by (Used in) Financing Activity, Including Discontinued Operation | Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit. |
| Common Stock Shares Outstanding | us-gaap/2025 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Payments Of Debt Issuance Costs | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments of Debt Issuance Costs | The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. |
| Treasury Stock Reissued At Lower Than Repurchase Price | us-gaap/2025 | 0 | 0 | monetary | D | D | Treasury Stock Reissued at Lower than Repurchase Price | In cases when treasury stock is reissued at a price lower than the cost to repurchase, the excess difference between the selling price and cost to repurchase is charged against retained earnings (assuming that all APIC arising from treasury stock transactions has first been exhausted). |
| Assets | us-gaap/2025 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Liabilities And Stockholders Equity | us-gaap/2025 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Net Income Loss | us-gaap/2025 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Other Nonoperating Income Expense | us-gaap/2025 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Stockholders Equity | us-gaap/2025 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2025 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Goodwill | us-gaap/2025 | 0 | 0 | monetary | I | D | Goodwill | Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Proceeds From Other Operating Activities | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from Other Operating Activity | Amount of cash inflow from operating activity, classified as other. |
| Other Comprehensive Income Loss Net Of Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Net of Tax | Amount after tax and reclassification adjustments of other comprehensive income (loss). |
| Payments To Suppliers And Employees | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments to Suppliers and Employees | Cash payments to suppliers for goods and services provided and to employees for services provided. |
| Repayments Of Long Term Debt | us-gaap/2025 | 0 | 0 | monetary | D | C | Repayments of Long-Term Debt | The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. |
| Gross Profit | us-gaap/2025 | 0 | 0 | monetary | D | C | Gross Profit | Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. |
| Income Tax Expense Benefit | us-gaap/2025 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Inventory Net | us-gaap/2025 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Liabilities | us-gaap/2025 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Accounts Payable Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | us-gaap/2025 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Interest Paid Net | us-gaap/2025 | 0 | 0 | monetary | D | C | Interest Paid, Excluding Capitalized Interest, Operating Activity | Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. |
| Payments To Acquire Investments | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments to Acquire Investments | The cash outflow associated with the purchase of all investments (debt, security, other) during the period. |
| Preferred Stock Shares Authorized | us-gaap/2025 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Prepaid Expense Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Prepaid Expense, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. |
| Proceeds From Sale Of Available For Sale Securities Debt | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from Sale of Debt Securities, Available-for-Sale | Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). |
| Restricted Cash Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Restricted Cash, Current | Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. |
| Treasury Stock Common Shares | us-gaap/2025 | 0 | 0 | shares | I | Treasury Stock, Common, Shares | Number of previously issued common shares repurchased by the issuing entity and held in treasury. | |
| Treasury Stock Value Acquired Cost Method | us-gaap/2025 | 0 | 0 | monetary | D | D | Treasury Stock, Value, Acquired, Cost Method | Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2025 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2025 | 0 | 0 | monetary | I | D | Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation | Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Cost Of Goods And Services Sold | us-gaap/2025 | 0 | 0 | monetary | D | D | Cost of Product and Service Sold | The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. |
| Treasury Stock Value | us-gaap/2025 | 0 | 0 | monetary | I | D | Treasury Stock, Value | The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. |
| Long Term Investments | us-gaap/2025 | 0 | 0 | monetary | I | D | Long-Term Investments | The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). |
| Marketable Securities Unrealized Gain Loss | us-gaap/2025 | 0 | 0 | monetary | D | C | Marketable Security, Unrealized Gain (Loss) | Amount of unrealized gain (loss) on investment in marketable security. |
| Preferred Stock Value | us-gaap/2025 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Preferred Units Outstanding | us-gaap/2025 | 0 | 0 | shares | I | Preferred Units, Outstanding | The number of preferred units outstanding. | |
| Net Cash Provided By Used In Operating Activities | us-gaap/2025 | 0 | 0 | monetary | D | Cash Provided by (Used in) Operating Activity, Including Discontinued Operation | Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity. | |
| Other Assets Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Other Assets, Current | Amount of current assets classified as other. |
| Retained Earnings Accumulated Deficit | us-gaap/2025 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Common Stock Value | us-gaap/2025 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Income Taxes Paid Net | us-gaap/2025 | 0 | 0 | monetary | D | C | Income Taxes Paid, Net | Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. |
| Allowance For Doubtful Accounts Receivable Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Accounts Receivable, Allowance for Credit Loss, Current | Amount of allowance for credit loss on accounts receivable, classified as current. |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. |
| Taxes Payable Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Taxes Payable, Current | Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0000012208-25-000026 | 2 | 9 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2025 | Cash and cash equivalents | 0 |
| 0000012208-25-000026 | 2 | 10 | BS | 0 | H | Short Term Investments | us-gaap/2025 | Short-term investments | 0 |
| 0000012208-25-000026 | 2 | 11 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2025 | Accounts receivable, net | 0 |
| 0000012208-25-000026 | 2 | 12 | BS | 0 | H | Inventory Net | us-gaap/2025 | Inventory | 0 |
| 0000012208-25-000026 | 2 | 13 | BS | 0 | H | Prepaid Expense Current | us-gaap/2025 | Prepaid expenses | 0 |
| 0000012208-25-000026 | 2 | 14 | BS | 0 | H | Other Assets Current | us-gaap/2025 | Other current assets | 0 |
| 0000012208-25-000026 | 2 | 15 | BS | 0 | H | Assets Current | us-gaap/2025 | Total current assets | 0 |
| 0000012208-25-000026 | 2 | 16 | BS | 0 | H | Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | us-gaap/2025 | Property, plant and equipment, net | 0 |
| 0000012208-25-000026 | 2 | 17 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2025 | Operating lease right-of-use assets | 0 |
| 0000012208-25-000026 | 2 | 18 | BS | 0 | H | Goodwill | us-gaap/2025 | Goodwill, net | 0 |
| 0000012208-25-000026 | 2 | 19 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2025 | Purchased intangibles, net | 0 |
| 0000012208-25-000026 | 2 | 20 | BS | 0 | H | Long Term Investments | us-gaap/2025 | Other investments | 0 |
| 0000012208-25-000026 | 2 | 21 | BS | 0 | H | Other Assets | us-gaap/2025 | Other assets | 0 |
| 0000012208-25-000026 | 2 | 22 | BS | 0 | H | Assets | us-gaap/2025 | Assets | 0 |
| 0000012208-25-000026 | 2 | 24 | BS | 0 | H | Accounts Payable Current | us-gaap/2025 | Accounts payable | 0 |
| 0000012208-25-000026 | 2 | 25 | BS | 0 | H | Employee Related Liabilities Current | us-gaap/2025 | Accrued payroll and employee benefits | 0 |
| 0000012208-25-000026 | 2 | 26 | BS | 0 | H | Notes And Loans Payable Current | us-gaap/2025 | Current maturities of long-term debt and notes payable | 0 |
| 0000012208-25-000026 | 2 | 27 | BS | 0 | H | Taxes Payable Current | us-gaap/2025 | Income and other taxes payable | 0 |
| 0000012208-25-000026 | 2 | 28 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2025 | Current operating lease liabilities | 0 |
| 0000012208-25-000026 | 2 | 29 | BS | 0 | H | Other Liabilities Current | us-gaap/2025 | Other current liabilities | 0 |
| 0000012208-25-000026 | 2 | 30 | BS | 0 | H | Liabilities Current | us-gaap/2025 | Total current liabilities | 0 |
| 0000012208-25-000026 | 2 | 31 | BS | 0 | H | Long Term Debt Noncurrent | us-gaap/2025 | Long-term debt, net of current maturities | 0 |
| 0000012208-25-000026 | 2 | 32 | BS | 0 | H | Deferred Income Tax Liabilities Net | us-gaap/2025 | Deferred income taxes | 0 |
| 0000012208-25-000026 | 2 | 33 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2025 | Operating lease liabilities | 0 |
| 0000012208-25-000026 | 2 | 34 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2025 | Other long-term liabilities | 0 |
| 0000012208-25-000026 | 2 | 35 | BS | 0 | H | Liabilities | us-gaap/2025 | Total liabilities | 0 |
| 0000012208-25-000026 | 2 | 36 | BS | 0 | H | Preferred Units Outstanding | us-gaap/2025 | Preferred Units, Outstanding | 0 |
| 0000012208-25-000026 | 2 | 37 | BS | 0 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2025 | Preferred Stock, Par or Stated Value Per Share | 0 |
| 0000012208-25-000026 | 2 | 39 | BS | 0 | H | Common Stock Value | us-gaap/2025 | Common stock | 0 |
| 0000012208-25-000026 | 2 | 40 | BS | 0 | H | Additional Paid In Capital | us-gaap/2025 | Additional paid-in capital | 0 |
| 0000012208-25-000026 | 2 | 41 | BS | 0 | H | Treasury Stock Value | us-gaap/2025 | Treasury stock | 1 |
| 0000012208-25-000026 | 2 | 42 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2025 | Retained earnings | 0 |
| 0000012208-25-000026 | 2 | 43 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2025 | Accumulated other comprehensive loss | 0 |
| 0000012208-25-000026 | 2 | 44 | BS | 0 | H | Stockholders Equity | us-gaap/2025 | Total stockholders' equity | 0 |
| 0000012208-25-000026 | 2 | 45 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2025 | Total liabilities and stockholders' equity | 0 |
| 0000012208-25-000026 | 2 | 46 | BS | 0 | H | Preferred Stock Value | us-gaap/2025 | Preferred Stock, Value, Issued | 0 |
| 0000012208-25-000026 | 2 | 47 | BS | 0 | H | Preferred Stock Shares Authorized | us-gaap/2025 | Preferred Stock, Par or Stated Value Per Share | 0 |
| 0000012208-25-000026 | 3 | 10 | BS | 1 | H | Allowance For Doubtful Accounts Receivable Current | us-gaap/2025 | Accounts receivable allowance for doubtful accounts | 0 |
| 0000012208-25-000026 | 3 | 11 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2025 | Common Stock, Shares, Issued | 0 |
| 0000012208-25-000026 | 3 | 12 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2025 | Common Stock, Shares, Outstanding | 0 |
| 0000012208-25-000026 | 3 | 13 | BS | 1 | H | Treasury Stock Common Shares | us-gaap/2025 | Treasury Stock, Shares | 0 |
| 0000012208-25-000026 | 3 | 14 | BS | 1 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2025 | Cash and cash equivalents | 0 |
| 0000012208-25-000026 | 3 | 15 | BS | 1 | H | Short Term Investments | us-gaap/2025 | Short-term investments | 0 |
| 0000012208-25-000026 | 3 | 16 | BS | 1 | H | Accounts Receivable Net Current | us-gaap/2025 | Accounts receivable, net | 0 |
| 0000012208-25-000026 | 3 | 17 | BS | 1 | H | Inventory Net | us-gaap/2025 | Total Inventory | 0 |
| 0000012208-25-000026 | 3 | 18 | BS | 1 | H | Prepaid Expense Current | us-gaap/2025 | Prepaid expenses | 0 |
| 0000012208-25-000026 | 3 | 19 | BS | 1 | H | Other Assets Current | us-gaap/2025 | Other current assets | 0 |
| 0000012208-25-000026 | 3 | 20 | BS | 1 | H | Assets Current | us-gaap/2025 | Total current assets | 0 |
| 0000012208-25-000026 | 3 | 21 | BS | 1 | H | Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | us-gaap/2025 | Property, plant and equipment, net | 0 |
| 0000012208-25-000026 | 3 | 22 | BS | 1 | H | Operating Lease Right Of Use Asset | us-gaap/2025 | Operating lease right-of-use assets | 0 |
| 0000012208-25-000026 | 3 | 23 | BS | 1 | H | Goodwill | us-gaap/2025 | Goodwill, net | 0 |
| 0000012208-25-000026 | 3 | 24 | BS | 1 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2025 | Purchased intangibles, net | 0 |
| 0000012208-25-000026 | 3 | 25 | BS | 1 | H | Long Term Investments | us-gaap/2025 | Other investments | 0 |
| 0000012208-25-000026 | 3 | 26 | BS | 1 | H | Other Assets | us-gaap/2025 | Other assets | 0 |
| 0000012208-25-000026 | 3 | 27 | BS | 1 | H | Assets | us-gaap/2025 | Assets | 0 |
| 0000012208-25-000026 | 4 | 1 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2025 | Net sales | 0 |
| 0000012208-25-000026 | 4 | 2 | IS | 0 | H | Cost Of Goods And Services Sold | us-gaap/2025 | Cost of goods sold | 0 |
| 0000012208-25-000026 | 4 | 3 | IS | 0 | H | Gross Profit | us-gaap/2025 | Gross profit | 0 |
| 0000012208-25-000026 | 4 | 4 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2025 | Selling, general and administrative expense | 0 |
| 0000012208-25-000026 | 4 | 5 | IS | 0 | H | Research And Development Expense | us-gaap/2025 | Research and Development Expense | 0 |
| 0000012208-25-000026 | 4 | 6 | IS | 0 | H | Operating Income Loss | us-gaap/2025 | Segment profit (loss) | 0 |
| 0000012208-25-000026 | 4 | 7 | IS | 0 | H | Interest Expense | us-gaap/2025 | Interest expense | 0 |
| 0000012208-25-000026 | 4 | 8 | IS | 0 | H | Foreign Currency Transaction Gain Loss Before Tax | us-gaap/2025 | Foreign exchange (gains) losses, net | 1 |
| 0000012208-25-000026 | 4 | 9 | IS | 0 | H | Marketable Securities Unrealized Gain Loss | us-gaap/2025 | Marketable Securities, Unrealized (Gain) Loss | 1 |
| 0000012208-25-000026 | 4 | 10 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2025 | Other Nonoperating Income (Expense) | 0 |
| 0000012208-25-000026 | 4 | 11 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2025 | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | 0 |
| 0000012208-25-000026 | 4 | 12 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2025 | (Provision) benefit for income taxes | 1 |
| 0000012208-25-000026 | 4 | 13 | IS | 0 | H | Net Income Loss | us-gaap/2025 | Net income attributable to Bio-Rad | 0 |
| 0000012208-25-000026 | 4 | 15 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2025 | Net income per share basic attributable to Bio-Rad | 0 |
| 0000012208-25-000026 | 4 | 16 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2025 | Weighted average common shares - basic | 0 |
| 0000012208-25-000026 | 4 | 18 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2025 | Net income per share diluted attributable to Bio-Rad | 0 |
| 0000012208-25-000026 | 4 | 19 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2025 | Weighted average common shares - diluted | 0 |
| 0000012208-25-000026 | 5 | 5 | CI | 0 | H | Net Income Loss | us-gaap/2025 | Net Income (Loss) Attributable to Parent | 0 |
| 0000012208-25-000026 | 5 | 6 | CI | 0 | H | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2025 | Foreign currency translation adjustments | 0 |
| 0000012208-25-000026 | 5 | 7 | CI | 0 | H | Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2025 | Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent | 1 |
| 0000012208-25-000026 | 5 | 8 | CI | 0 | H | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | us-gaap/2025 | Net unrealized holding gains (losses) on available-for-sale investments net of tax expense | 0 |
| 0000012208-25-000026 | 5 | 9 | CI | 0 | H | Other Comprehensive Income Loss Net Of Tax | us-gaap/2025 | Total other comprehensive income (loss) net of tax | 0 |
| 0000012208-25-000026 | 5 | 10 | CI | 0 | H | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | us-gaap/2025 | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | 0 |
| 0000012208-25-000026 | 6 | 6 | CF | 0 | H | Proceeds From Customers | us-gaap/2025 | Cash received from customers | 0 |
| 0000012208-25-000026 | 6 | 7 | CF | 0 | H | Payments To Suppliers And Employees | us-gaap/2025 | Cash paid to suppliers and employees | 1 |
| 0000012208-25-000026 | 6 | 8 | CF | 0 | H | Interest Paid Net | us-gaap/2025 | Interest paid, net | 1 |
| 0000012208-25-000026 | 6 | 9 | CF | 0 | H | Income Taxes Paid Net | us-gaap/2025 | Income tax payments, net | 1 |
| 0000012208-25-000026 | 6 | 10 | CF | 0 | H | Proceeds From Other Operating Activities | us-gaap/2025 | Investment proceeds and miscellaneous receipts, net | 0 |
| 0000012208-25-000026 | 6 | 11 | CF | 0 | H | Paymentsforproceedsfromderivativeinstrumentsoperatingactivities | 0000012208-25-000026 | Proceeds from forward foreign exchange contracts, net | 1 |
| 0000012208-25-000026 | 6 | 12 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2025 | Net cash provided by operating activities | 0 |
| 0000012208-25-000026 | 6 | 14 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2025 | Capital expenditures | 1 |
| 0000012208-25-000026 | 6 | 15 | CF | 0 | H | Payments To Acquire Investments | us-gaap/2025 | Payments for purchases of marketable securities and investments | 1 |
| 0000012208-25-000026 | 6 | 16 | CF | 0 | H | Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | us-gaap/2025 | Proceeds from maturities of marketable securities and investments | 0 |
| 0000012208-25-000026 | 6 | 17 | CF | 0 | H | Proceeds From Sale Of Available For Sale Securities Debt | us-gaap/2025 | Proceeds from Sale of Debt Securities, Available-for-sale | 0 |
| 0000012208-25-000026 | 6 | 18 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2025 | Net cash used in investing activities | 0 |
| 0000012208-25-000026 | 6 | 20 | CF | 0 | H | Repayments Of Long Term Debt | us-gaap/2025 | Payments on long-term borrowings | 1 |
| 0000012208-25-000026 | 6 | 21 | CF | 0 | H | Payments Of Debt Issuance Costs | us-gaap/2025 | Payments for debt issuance costs | 1 |
| 0000012208-25-000026 | 6 | 22 | CF | 0 | H | Proceeds From Issuance Of Common Stock | us-gaap/2025 | Proceeds from Issuance of Common Stock | 0 |
| 0000012208-25-000026 | 6 | 23 | CF | 0 | H | Payments For Repurchase Of Common Stock | us-gaap/2025 | Payments for purchases of treasury stock | 1 |
| 0000012208-25-000026 | 6 | 24 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2025 | Net cash used in financing activities | 0 |
| 0000012208-25-000026 | 6 | 25 | CF | 0 | H | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2025 | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | 0 |
| 0000012208-25-000026 | 6 | 26 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2025 | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | 0 |
| 0000012208-25-000026 | 6 | 27 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2025 | Beginning Cash, Cash Equivalents, and Restricted Cash | 0 |
| 0000012208-25-000026 | 6 | 28 | CF | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2025 | Cash and cash equivalents | 0 |
| 0000012208-25-000026 | 6 | 29 | CF | 0 | H | Restricted Cash Current | us-gaap/2025 | Restricted Cash, Current | 0 |
| 0000012208-25-000026 | 6 | 30 | CF | 0 | H | Restricted Cash Noncurrent | us-gaap/2025 | Restricted Cash, Noncurrent | 0 |
| 0000012208-25-000026 | 6 | 31 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2025 | Ending Cash, Cash Equivalents, and Restricted Cash | 0 |
| 0000012208-25-000026 | 7 | 11 | EQ | 0 | H | Stockholders Equity | us-gaap/2025 | Total Stockholders' Equity | 0 |
| 0000012208-25-000026 | 7 | 12 | EQ | 0 | H | Net Income Loss | us-gaap/2025 | Net Income (Loss) Attributable to Parent | 0 |
| 0000012208-25-000026 | 7 | 13 | EQ | 0 | H | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2025 | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | 0 |
| 0000012208-25-000026 | 7 | 14 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2025 | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | 0 |
| 0000012208-25-000026 | 7 | 15 | EQ | 0 | H | Proceeds From Issuance Of Common Stock | us-gaap/2025 | Proceeds from Issuance of Common Stock | 1 |
| 0000012208-25-000026 | 7 | 16 | EQ | 0 | H | Treasury Stock Reissued At Lower Than Repurchase Price | us-gaap/2025 | Treasury Stock Reissued at Lower than Repurchase Price | 1 |
| 0000012208-25-000026 | 7 | 17 | EQ | 0 | H | Treasury Stock Value Acquired Cost Method | us-gaap/2025 | Treasury Stock, Value, Acquired, Cost Method | 1 |
| 0000012208-25-000026 | 7 | 18 | EQ | 0 | H | Stockholders Equity | us-gaap/2025 | Total Stockholders' Equity | 0 |
| 0000012208-25-000026 | 7 | 19 | EQ | 0 | H | Stock Issued During Period Value Treasury Stock Reissued | us-gaap/2025 | Stock Issued During Period, Value, Treasury Stock Reissued | 1 |
| 0000012208-25-000026 | 7 | 20 | EQ | 0 | H | Stock Repurchased During Period Excise Tax Amount | 0000012208-25-000026 | Stock Repurchased During Period, Excise Tax, Amount | 1 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |